Breaking Finance News

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to Hold in a statement released on Tuesday October 04, 2016.

On 8/15/2016, Vetr Inc. released a statement on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) upped the target price from $0.00 to $473.05 that suggested an upside of 0.13%.

Having a price of $401.37, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) traded 0.03% higher on the day. With the last close up 2.93% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Regeneron Pharmaceuticals Inc has recorded a 50-day average of $404.40 and a two hundred day average of $391.48. Volume of trade was down over the average, with 145,040 shares of REGN changing hands under the typical 761,978

Performance Chart

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

With a total market value of $0, Regeneron Pharmaceuticals Inc has price-earnings ratio of 62.86 with a one year low of $329.09 and a one year high of $592.59 .

A total of 21 analysts have released a report on Regeneron Pharmaceuticals Inc. Eight analysts rating the company a strong buy, six analysts rating the company a buy, eleven analysts rating the company a hold, one analyst rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $475.76.

More About Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company's segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. Its marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. Its other products include Sarilumab (REGN88), Dupilumab (REGN668), REGN2222, Fasinumab (REGN475), REGN2810, REGN2176-3, Evinacumab (REGN1500) and REGN1908-1909.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *